Demographics and clinical features associated with abnormal small bowel motility in systemic sclerosis
- PMID: 39374539
- PMCID: PMC12048077
- DOI: 10.1093/rheumatology/keae542
Demographics and clinical features associated with abnormal small bowel motility in systemic sclerosis
Abstract
Objective: The small bowel is affected in up to 50% of systemic sclerosis (SSc) patients, and some patients experience severe complications. Our aim was to use specific statistical methods to compare demographic and clinical features of SSc patients with and without abnormal small bowel to better characterize patients at risk for this complication.
Methods: SSc patients with gastrointestinal symptoms were prospectively enrolled and underwent a scintigraphy-based whole gut transit (WGT) study. A cross-sectional analysis was performed comparing clinical features between patients with and without abnormal small bowel transit by WGT. Univariate logistic regression models and multivariable models were used to examine the relationship between clinical features and abnormal small bowel transit.
Results: Of 130 patients enrolled in this study, 22 had abnormal small bowel transit. SSc patients with abnormal small bowel transit were more likely to be male [odds ratio (OR) = 3.70; 95% CI: 1.07, 12.50; P = 0.038] and have more severe cardiac involvement (OR = 3.98; 95% CI: 1.10, 14.38; P = 0.035), while they were less likely to have sicca symptoms (OR = 0.30; 95% CI: 0.10, 0.94; P = 0.039). In multivariable analyses, sicca symptoms (OR = 0.28; 95% CI: 0.08, 0.96; P = 0.043) remained negatively associated with abnormal small bowel transit. Additionally, SSc patients with abnormal small bowel transit had higher mortality than patients with normal small bowel transit [hazard ratio (HR) = 4.57; 95% CI: 1.58, 13.24; P = 0.005].
Conclusions: These findings suggest that patients with abnormal small bowel transit in SSc are more likely to be male, have more severe cardiac involvement, higher mortality and fewer sicca symptoms. Recognizing this patient subgroup is essential for risk stratification and optimizing clinical care.
Keywords: gastrointestinal; motility; scleroderma; small bowel; systemic sclerosis.
© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Figures
References
-
- Steen VD. The many faces of scleroderma. Rheum Dis Clin North Am 2008;34:1–15. - PubMed
-
- Butt S, Emmanuel A. Systemic sclerosis and the gut. Expert Rev Gastroenterol Hepatol 2013;7:331–9. - PubMed
-
- Forbes A, Marie I. Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology (Oxford) 2009;48(Suppl 3):iii36–9. - PubMed
-
- McMahan ZH, Tucker AE, Perin J et al. Relationship between gastrointestinal transit, medsger gastrointestinal severity, and University of California–Los Angeles Scleroderma Clinical Trial Consortium gastrointestinal tract 2.0 symptoms in patients with systemic sclerosis. Arthritis Care Res (Hoboken) 2022;74:442–50. - PMC - PubMed
-
- Steen VD, Medsger TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437–44. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical